key: cord-0798814-41btvlrw
authors: Chan, Huan-Tee; Chao, Chien-Ming; Lai, Chih-Cheng
title: Sofosbuvir/daclatasvir in the treatment of COVID-19 infection: a meta-analysis
date: 2020-12-26
journal: J Infect
DOI: 10.1016/j.jinf.2020.12.021
sha: 538c538aac2e09f7807f1c7b20a2c10936cb8cce
doc_id: 798814
cord_uid: 41btvlrw

nan

We read with great interest with the review article by Tu et al, 1 in which several potential anti-viral agents, including lopinavir/ritonavir, ribavirin, arbidol, remdesivir, oseltamivir, nafamostat, favipiravir, nitazoxanide and sofosbuvir could be considered as treatment options. However, the studies investigating the usefulness for most of these agents is lack. Recently, four studies [2] [3] [4] [5] which investigated the efficacy of sofosbuvir plus daclatasvir in combination for COVID-19 patients with mild to severe diseases. All of them 2-5 demonstrated the beneficial effect of sofosbuvir-daclatasvir on the outcomes of COVID-19 patients; however, most of the differences between sofosbuvir-daclatasvir and comparator in terms of these clinical outcomes, such as clinical recovery, length of hospital stays and mortality did not reach statistical significance. These insignificant differences may be attributed to the small case number in each study [2] [3] [4] [5] , so all three studies concluded that further large-scale study is warranted. Before that, we believe an integrated analysis of these four studies 2-5 can provide more strong evidence than each of them. Therefore, we conducted this pooled analysis of these studies. Although sofosbuvir/daclatasvir-based treatment group was associated with lower rate of MV uses than standard care/other alternative treatment group, the difference did not reach statistical significance (5.3% vs 15.8%; RR, 0.40; 95% CI, 0.10-01.73; I 2 = 15%). The similar trend was observed regarding the length of hospital stay in the pooled analysis of three studies. [2] [3] [4] Those receiving sofosbuvir/daclatasvir-based treatment was associated with numerically shorter length of hospital stay than control group, but the difference did not reach statistical significance (mean difference, -1.86; 95% CI, -3.88 to 0.16; I 2 = 81%).

Based on the finding of this study, sofosbuvir/daclatasvir-based treatment was associated with a higher clinical recovery rate, a lower mortality rate and a less ICU admission than standard care or other alternative treatment in the management of patients with COVID-19 infections. In addition, we observed the trend about the less MV use and shorter length of hospital stay among the patients receiving sofosbuvir/daclatasvir-based treatment than the control group. In summary, our finding indicates that sofosbuvir/daclatasvir can a potential therapeutic agent for COVID-19 patients. This is an important finding in COVID-19 pandemic due to the truly effective weapon against SARS-CoV-2 is limited. 6, 7 However, our findings should be interpreted cautiously. Only three studies of small case number were included in this analysis and all were conducted in Iran. This issue may limit the generalizability of our findings. However, the heterogeneity regarding the clinical outcomes among these three studies were small, which could limit the bias in this study.

In conclusion, sofosbuvir/daclatasvir-based treatment can be associated with a better clinical outcome than standard care or other comparators for COVID-19 infection.

However, more randomized control trials are warranted to confirm our findings and also investigate the safety of sofosbuvir/daclatasvir for treating COVID-19 patients.

Current epidemiological and clinical features of COVID-19; a global perspective from

Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial

The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19

Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial

Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial

Treatment options for COVID-19: The reality and challenges

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

The authors declare that they have no competing interest